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Objective/purpose
T h ep r e v a l e n c eo fa s t h m ai nC a n a d a( a n dw o r l d w i d e )
has been increasing over the last 20 years with currently
over 3 million Canadians suffering from it. Asthma
appears to result from environmental influences direct-
ing a genetically predisposed host towards a pro-allergic,
Th2-dominated immune response. Studies in humans
and animals identify the time around birth and early
infancy as a period during which the decision of pro-
allergic versus non-allergic immune responses to envir-
onmental stimuli appears to be made. Presumably this is
the reason why the incidence of first diagnosis is highest
in infants and children, although asthma can occur at
any age. The very fact that all three components (envir-
onmental, genetic and developmental) are necessary for
asthma to occur also offers the opportunity to intervene
e a r l yi nl i f et h r o u g he.g. vaccination against allergies.
Vaccination as a strategy to prevent or cure asthma is a
tremendous opportunity. An ideal vaccine would be one
that prevents or cures asthma after only one dose and
protects for life. It is well established that the whole
heat-killed bacterium Listeria monocytogenes (Lm)g i v e n
as an adjuvant along with model allergens effectively
prevent allergic sensitization and/or allergic inflamma-
tion in adult animals following local allergen challenge.
We have successfully developed a novel, live, but highly
attenuated neonatal vaccine platform based on the bac-
terium Listeria monocytogenes (Lm). Our published data
s u g g e s tt h a to u rLm-based vaccine platform is capable
of inducing strong anti-allergic immune responses for
an entire life only after one dose given to newborn
mice. Now we have investigated whether our Lm-based
vaccine platform will provide protection from allergic
reactions upon challenge with the allergen, after only
one immunization given around birth. Our specific aim
addressed the following objective: Do our Listeria
monocytogenes vaccine strains producing model aller-
gen ovalbumin (OVA) and inducing a strong Th1
response, prevent allergic reactions upon challenge
with the allergen in a neonatal mouse model?
Methods
We focused on assessing protection against OVA-aller-
gic reactions in mice that were immunized i.p.a sn e w -
borns with heat-killed Lm vs. those vaccinated with our
live-attenuated Lm-OVA or Lm or NaCl alone. We have
coupled immune-focused analysis (total and differential
counts of broncho-alveolar lavages, OVA-stimulation
assays on lung cells and splenocytes, measurement of
IgG1, IgE and IgG2a levels in serum) with the histo-
pathological examination of lungs. Furthermore, we
started to delineate the molecular mechanisms (Realtime
PCR of immunological-relevant genes) underlying the
surprisingly high efficacy of the live-attenuated Lm-
based vaccine approach.
Findings
Our novel Lm-based vaccine platform was particularly
safe and very-well tolerated in newborns. Using this
live-attenuated platform in comparison to the already
established heat-killed Lm approach in adult mice, we
determined that mice immunized as newborns with our
live Lm vaccine platform producing ovalbumin were
indeed entirely protected from allergic OVA-sensitiza-
tion after just one immunization given around birth.
Furthermore, our live Lm-based approach was far super-
ior to heat-killed Lm-based approaches, as it resulted in
an almost complete inhibition of the recruitment of
inflammatory cells into lungs of immunized mice after
OVA-challenge. Interestingly, mice immunized with our
live attenuated Lm strain not expressing OVA but sensi-
tized and challenged with OVA showed inhibition of the
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© 2010 Loeffler et al; licensee BioMed Central Ltd.recruitment of only eosinophils, but not inhibition of
any of the other inflammatory cells into the lungs upon
challenge.
Deliverables
The analysis of our single dose Lm-vaccination strategy
in mice represents the first attempt to truly test the abil-
ity of a neonatal vaccine to prevent allergic reactions in
early in life, but for the entire life. We furthermore
expect to be able to optimize this approach to apply our
Lm-based vaccines against food allergies or other clini-
cally relevant forms of allergic disease as an immune-
modulatory based therapeutic intervention in previously
sensitized individuals.
Relevance
It offers immediate translation into human vaccine
design and current immunization policies against
asthma, as Listeria monocytogenes has already been
approved for human applications.
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